STAT
JANUARY 14, 2025
And the findings may provide further impetus for legislative action to curb practices that critics say contribute to the rising cost of prescription drugs. For the second time in less than a year, the U.S.
STAT
AUGUST 8, 2024
How will we know if the the government gets a good deal in the first round of drug pricing negotiations? And has Allison thought about anything other than venture capital for the last couple of months? We discuss all that and more on this week’s episode of “The Readout LOUD.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JUNE 7, 2023
BOSTON — The drug industry has spent the past year speaking against new mechanisms that could limit how much governments or insurers pay for certain new medicines. Robert Califf, the Food and Drug Administration chief, walked on stage Wednesday and told a crowd of biotech leaders that drug costs needed fixing.
STAT
MAY 6, 2025
can stay competitive in science, biomedical innovation, and drug development. We’ve Sign up to get our biotech newsletter in your inbox. Good morning, there’s been a lot of discussion lately about how the U.S. We’ve got several pieces of news relevant to that issue today.
STAT
FEBRUARY 9, 2024
Also, Moderna’s RSV vaccine efficacy seems lackluster compared to competitors, and the Bernie Sanders drug pricing song-and-dance did not seem to faze pharma CEOs. Our podcast this week centers exclusively on a tantalizing subject: Artificial intelligence in biotech. Give it a listen. Read the rest…
STAT
SEPTEMBER 26, 2023
Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so can lead to its most significant revenue period, according to a recent analysis published by the Initiative for Medicines, Access & Knowledge, or I-MAK, a nonprofit advocating for drug pricing reforms.
STAT
JUNE 5, 2023
He hopes to use his experience across the drug development process to improve the biotech industry’s reputation in Washington, following a bruising lobbying fight the industry lost when Democrats gave Medicare the power to negotiate drug prices, and the organization’s messy separation from its former CEO last year.
Expert insights. Personalized for you.
357 
Let's personalize your content